BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 9427043)

  • 1. In vivo effects of COPP protocol on onco- and suppressor gene expression in a 'follow up study'.
    Ember I; Kiss I; Raposa T
    In Vivo; 1997; 11(5):399-402. PubMed ID: 9427043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo effects of CHOP protocol on onco and suppressor gene expression: follow-up study.
    Ember I; Kiss I; Raposa T; Nowrasteh G; Matolcsy A
    In Vivo; 1998; 12(5):489-94. PubMed ID: 9827356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of ABVD therapeutic protocol on oncogene and tumor suppressor gene expression in CBA/Ca mice.
    Ember I; Kiss I; Ghodratollah N; Raposa T
    Anticancer Res; 1998; 18(2A):1149-52. PubMed ID: 9615780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo effects of cyclophosphamide on oncogene and suppressor gene expression in a "follow up" study.
    Ember I; Kiss I
    Anticancer Res; 1997; 17(5A):3593-7. PubMed ID: 9413208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early effects of different cytostatic protocols for head and neck cancer on oncogene activation in animal experiments.
    Németh A; Nadasi E; Gyöngyi Z; Olasz L; Nyarady Z; Ember A; Kvarda A; Bujdoso L; Arany I; Kiss I; Csejtey I; Ember I
    Anticancer Res; 2003; 23(6C):4831-5. PubMed ID: 14981932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of E-2-(4'-methoxybenzylidene)-1-benzosuberone on the 7,12-dimethylbenz[alpha]anthracene-induced onco/suppressor gene action in vivo. I: A 24-hour experiment.
    Perjési P; Bayer Z; Ember I
    Anticancer Res; 2000; 20(1A):475-81. PubMed ID: 10769699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of 7,12-dimethylbenz(a)anthracene on onco/suppressor gene action in vivo: a short-term experiment.
    Ember I; Kiss I; Pusztai Z
    Anticancer Res; 1998; 18(1A):445-7. PubMed ID: 9568117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of rancid corn oil on some onco/suppressor gene expressions in vivo. A short-term study.
    Perjési P; Pintér Z; Gyöngyi Z; Ember I
    Anticancer Res; 2002; 22(1A):225-30. PubMed ID: 12017293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different H2 haplotypes have a strong influence on oncogene action.
    Ember I; Kiss I; Nowrasteh G
    Anticancer Res; 1999; 19(2A):1181-5. PubMed ID: 10368672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early modification of c-myc, Ha-ras and p53 expressions by N-methyl-N-nitrosourea.
    Budán F; Varjas T; Nowrasteh G; Varga Z; Boncz I; Cseh J; Prantner I; Antal T; Pázsit E; Gobel G; Bauer M; Gracza T; Perjési P; Ember I; Gyöngyi Z
    In Vivo; 2008; 22(6):793-7. PubMed ID: 19181008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of cisplatin treatment on early activation of oncogenes in vivo.
    Németh A; Gyöngyi Z; Nádasi E; Ember A; Olasz L; Nyárády Z; Skapinyecz J; Ember I
    In Vivo; 2002; 16(5):307-10. PubMed ID: 12494868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of E-2-(4'-methoxybenzylidene)-1-benzosuberone on the 7,12-dimethylbenz[alpha]anthracene-induced onco/suppressor gene action in vivo II: A 48-hour experiment.
    Perjési P; Gyöngyi Z; Bayer Z
    Anticancer Res; 2000; 20(3A):1839-48. PubMed ID: 10928116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carcinogenic effects of cytostatic protocols in CBA/Ca mice.
    Ember I; Raposa T; Varga C; Herceg L; Kiss I
    In Vivo; 1995; 9(1):65-9. PubMed ID: 7545447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of different cytostatic protocols on oncogene expression in CBA/Ca mice.
    Ember I; Raposa T; Varga C; Kiss I
    Anticancer Res; 1995; 15(4):1285-8. PubMed ID: 7654010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in expression of onco- and suppressor genes in peripheral leukocytes--as potential biomarkers of chemical carcinogenesis.
    Gyöngyi Z; Ember I; Kiss I; Varga C
    Anticancer Res; 2001; 21(5):3377-80. PubMed ID: 11848497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early effect of cyclophosphamide on oncogene expression in vivo.
    Ember I; Kiss I; Vermes E
    In Vivo; 1998; 12(2):201-7. PubMed ID: 9627803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early effects of transplatin on oncogene activation in vivo.
    Németh A; Nádasi E; Beró A; Olasz L; Ember A; Kvarda A; Bujdosó L; Arany I; Csejtei A; Faluhelyi Z; Ember I
    Anticancer Res; 2004; 24(6):3997-4001. PubMed ID: 15736445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.
    Engert A; Diehl V; Franklin J; Lohri A; Dörken B; Ludwig WD; Koch P; Hänel M; Pfreundschuh M; Wilhelm M; Trümper L; Aulitzky WE; Bentz M; Rummel M; Sezer O; Müller-Hermelink HK; Hasenclever D; Löffler M
    J Clin Oncol; 2009 Sep; 27(27):4548-54. PubMed ID: 19704068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early modification of c-myc, Ha-ras and p53 expressions by chemical carcinogens (DMBA, MNU).
    Budán F; Varjas T; Nowrasteh G; Prantner I; Varga Z; Ember A; Cseh J; Gombos K; Pázsit E; Gobel G; Bauer M; Gracza T; Arany I; Perjési P; Ember I; Kiss I
    In Vivo; 2009; 23(4):591-8. PubMed ID: 19567395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carcinogenic potential of trans-2-hexenal is based on epigenetic effect.
    Nádasi E; Varjas T; Pajor L; Ember I
    In Vivo; 2005; 19(3):559-62. PubMed ID: 15875776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.